Takeda Pharmaceutical (TAK) Stock
NEW YORK STOCK EXCHANGE INC. · TAK
18.89
Fundamentals
Market cap
$60.39B
Price / Earnings ratio
-59.3x
Price / Sales ratio
2.1x
Price / Book ratio
1.3x
Return on assets
-0.0%
Ex-Dividend date
30 Sep 2025
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
1.7%
Debt / Equity ratio
N/A
Latest news
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan. It specializes in researching, developing, manufacturing, and marketing pharmaceutical products for various therapeutic areas. Takeda's mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine. Takeda has a diverse portfolio of products, including prescription medications, over-the-counter drugs, and vaccines. It focuses on areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees47,029
CEOMs. Julie Kim
IPO DateOct 27, 2008
HeadquartersChuo, Japan
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Milano Furuta | CFO & Director | 1978 |
| Dr. Andrew S. Plump M.D., Ph.D. | President of Research & Development and Representative Director | 1965 |
| Ms. Julie Kim | CEO, President & Director | 1970 |
| Dr. Seigo Izumo | Chair of Management Board | — |
| Mr. Haruhiko Hirate | Member of Management Board | 1957 |
| Mr. Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of R&D Global Science & Biomedical Policy | 1975 |
| Michael Fox | Chief Operating Officer | — |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller | — |
| Mr. Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department | — |
| Mr. Gabriele Ricci | Chief Data & Technology Officer | 1978 |
Fundamentals
Valuation
Market cap$60.39B
Price-to-sales ratio2.09
Price-to-book value1.28
Price-earnings ratio-59.30
Return on Equity-2.00%
Return on Sales0.05%
Return on AssetsN/A
PEG ratio0.42
Earnings Per Share
Earnings Per Share$-0.32
Income Statement
Average volume2,142,318
EBITDA$5.79B
1 year high (52w)$19.10
1 year low (52w)$12.99
Dividend
Ex dividend date30 Sep 2025
Dividend amount$0.00
Dividend yield1.71%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



